H. Un. Son Espases
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sampol, Antonia
AML-12, NCT04687098: Risk-adapted Therapy for Primary Acute Myeloid Leukemia

Completed
2
1034
Europe
Idarubicin, Ida, Ara-C, HDAC, G-CSF, Pegfilgrastim, Allogeneic matched or unrelated donor transplant., Autologous peripheral blood stem cell transplant, Measurable residual disease, MRD
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Leukemia, Myeloid, Acute
07/22
11/22
VEN-A-QUI, NCT04687761: Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Recruiting
1/2
84
Europe
Azacitidine, Venetoclax, Quizartinib, Cytarabine
PETHEMA Foundation
Leukemia, Myeloid, Acute, De Novo, Age More 60yr
11/24
11/24
NCT05297240: Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Recruiting
N/A
170
Europe
Belantamab mafodotin
PETHEMA Foundation, GlaxoSmithKline
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
12/22
12/22
Raga, José María Sánchez
NCT05297240: Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Recruiting
N/A
170
Europe
Belantamab mafodotin
PETHEMA Foundation, GlaxoSmithKline
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
12/22
12/22

Download Options